PMID- 21813732
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20110804
IS  - 1945-1997 (Electronic)
IS  - 0098-6151 (Linking)
VI  - 111
IP  - 7 Suppl 5
DP  - 2011 Jul
TI  - Assessing cardiovascular risk factors and selecting agents to successfully treat 
      patients with type 2 diabetes mellitus.
PG  - S2-12
AB  - Type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease (CVD) share 
      a common pathogenic mechanism. The prevalence of each of these conditions is 
      increasing at an alarming rate. Despite the availability of several treatment 
      options for patients with T2DM and the use of intensive regimens combining 
      several antidiabetic drugs, less than half of all patients reach a target 
      glycosylated hemoglobin level of less than 7%. Given the rapid increase in the 
      number of patients with T2DM and obesity, as well as the CVD morbidity and 
      mortality associated with this burden, efforts must be made to change the course 
      of disease. The author reviews clinical trial data on the effect of glucose 
      control on CVD risk, the selection and timing of antihyperglycemic agents, the 
      management of associated CVD risk factors, and strategies to improve patient 
      adherence and acceptance-with the goal of assisting physicians in selecting 
      appropriate management strategies for their patients with T2DM.
FAU - Baldwin, Mark D
AU  - Baldwin MD
AD  - Dublin Medical Clinic II, 6350 Frantz Rd., Dublin, OH 43017-1382, USA. 
      mdb51@earthlink.net
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Osteopath Assoc
JT  - The Journal of the American Osteopathic Association
JID - 7503065
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Blood Glucose/*analysis
MH  - Cardiovascular Diseases/*epidemiology/prevention & control
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy/*epidemiology
MH  - Diabetic Angiopathies/epidemiology/prevention & control
MH  - Female
MH  - Humans
MH  - Hypertension/diagnosis/epidemiology
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incidence
MH  - Male
MH  - Obesity/*epidemiology/prevention & control
MH  - Prognosis
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Smoking/adverse effects/epidemiology
MH  - Survival Analysis
EDAT- 2011/08/10 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/08/05 06:00
PHST- 2011/08/05 06:00 [entrez]
PHST- 2011/08/10 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 111/7_suppl_5/S2 [pii]
PST - ppublish
SO  - J Am Osteopath Assoc. 2011 Jul;111(7 Suppl 5):S2-12.